Achard-Thiers Syndrome (ATS) is also known as ‘diabetic-bearded woman syndrome’ or diabète des femmes à barbe in the original French research report. It is a rare condition that affects post menopausal women, with key symptoms being type II diabetes mellitus and an increase in androgen production. Androgens are hormones such as testosterone that lead to male characteristics to be present. This can lead to symptoms such as hirsutism (hair growth around the face), acne and clitoral hypertrophy. Other features such as obesity, hypertension, and acanthosis nigricans (skin conditions with thickened, darkened skin) can also be present.¹

Discovered in 1921 by Emile Achard and Joseph Thiers, it was one of the first conditions to connect a metabolic disease and hyperandrogenic signs in older women. 

Past 

The 20th Century was an era of discovery in medicine, with the rise of endocrinology as a distinct medical area. The term hormone had been coined in 1905 by Ernest Starling,² and with it, the idea of internal secretions was gradually replacing the idea of humoral theories of disease. 

Diabetes research had a massive discovery in 1889, when Von Mering and Minkowski established the pancreas as key to glucose metabolism. In the 1900s, endocrine disorders were recognised by clinical signs and relied on descriptive medicine rather than assay and blood tests. This means that the unique syndrome of diabetes and virilisation indicated that this was a new condition. 

By the early 1900s, diabetes mellitus was increasingly prevalent and was understood to be caused by abnormal glucose metabolism. However, there was no distinction between type 1 (insulin-dependent) and type 2 (insulin-resistant). Societal context also shaped medical studies. Postmenopausal women were rarely the focus of endocrine studies, with signs such as hirsutism dismissed as cosmetic rather than pathological. Menopause was recognised as a physical and logical stage defined by amenorrhea (loss of period) and age, but not by hormonal lab values.⁴

Present

ATS is currently diagnosed primarily through the identification of characteristic findings in postmenopausal women. The key diagnostic features of ATS include Type 2 diabetes mellitus, signs of hyperandrogenism, as well as postmenopausal status.⁵ Obesity, hypertension and adrenal enlargement are also common in ATS. These symptoms are often progressive and can be dismissed as normal ageing. In order to confirm a diagnosis of ATS, a series of tests will be administered. A fasting glucose test is ordered in order to confirm insulin-resistant diabetes, as well as an HbA1c test.⁶ A serum androgen profile is taken, with elevated levels of testosterone suggesting hyperandrogenism. 

Other investigations are often required to rule out other causes that may present with similar clinical features. For example, MRIs or CT scans might be ordered to detect an adrenal adenoma or hyperplasia. Pelvic ultrasounds can help identify ovarian sources of androgen excess, such as androgen-secreting tumours. The main differential diagnosis includes Cushing’s syndrome, polycystic ovarian syndrome (PCOS) and androgen-producing neoplasm of the adrenal or ovary.⁷ While ATS is a clinical condition defined by the presence of Type 2 diabetes and signs of hyperandrogenism in postmenopausal women, it is not caused by a single pathology. ATS represents a phenotypic pattern that can have many different mechanisms, including adrenal hyperfunction or hormone-secreting tumours. Therefore, the presence of tumours does not rule out ATS completely, but might be part of the causative mechanism.⁸

A key issue in diagnosing ATS is the lack of clinical awareness. This is due to two major reasons: the lack of formal clinical guidelines and the rarity of the disease. It is critical that clinicians further explore the symptoms of postmenopausal women who present with type 2 diabetes and hyperandrogenic signs in order to establish an accurate diagnosis and cause. 

ATS can drastically change one's quality of life, particularly due to the dual burden of managing Type 2 diabetes and androgen excess. As Type 2 diabetes does not respond to insulin injections, the complications have to be mainly managed via careful lifestyle management, including dietary modifications and regular physical activity, in order to improve metabolic health.  Pharmacological interventions are often necessary. Spironolactone is an anti-androgen and aldosterone antagonist. It can directly block androgen receptors, which reduces the biological activity of androgens, helping reduce symptoms such as hirsutism and acne, which are common in ATS. The aldosterone antagonism is useful in treating ATS patients as it can help manage hypertension, which is often seen in patients with ATS. There is also some evidence to suggest that it can improve insulin sensitivity indirectly by improving hormonal balance.⁹ Metformin is also prescribed to those with ATS, as it can reduce glucose production by acting on the liver. It also increases glucose uptake in the muscle. This helps those with Type 2 diabetes manage their blood sugar levels. It can also reduce the production of androgens by decreasing the activity of insulin activation of theca cells in the overlay.¹⁰

Future

In order to provide better care for those with ATS, there needs to be an increase in research into the condition. However, it might be hard to close this research gap due to the rarity of the disease. There is a need for a better understanding of any genetic predisposition to the disease. Precision medicine is an emerging field that might allow for better care for individuals, using therapies such as metformin and insulin sensitisers. Whilst there are no clinical trials specific to ATS, there is research ongoing studying insulin resistance that could inform future treatment. 

The improvement of hormonal assays and imaging may allow for earlier detection of adrenal pathologies. With increased studies, there might be biomarkers that could clarify who is at risk of developing ATS, allowing a predictive screening program to be implemented. 

For the individual patients, their long-term prognosis is dependent on their individual cases and treatment. Focus should be on managing their symptoms and conditions, as well as on cardiovascular risk reduction and maintaining bone health. As this condition targets many areas of the body, as hormones are all over the body, multidisciplinary care models that combine endocrinology, psychiatry and dermatology should be used.  

Summary

Achard–Thiers Syndrome (ATS), first identified in 1921 by Achard and Thiers, is a rare condition seen mainly in postmenopausal women and characterised by the combination of Type 2 diabetes mellitus and hyperandrogenism. Historically, it stood out because, in the early 20th century, diabetes and endocrine disorders were still poorly understood, and signs like hirsutism in older women were often dismissed rather than medically investigated.

Today, ATS is diagnosed through the presence of insulin-resistant Type 2 diabetes, elevated androgen levels, and postmenopausal status, often alongside obesity, hypertension, and sometimes adrenal enlargement. Diagnosis requires ruling out similar conditions such as PCOS, Cushing’s syndrome, or androgen-producing tumours. A major challenge remains low clinical awareness and the absence of formal guidelines.

Management focuses on controlling diabetes and reducing androgen excess. Treatments may include lifestyle modifications, metformin, and anti-androgen drugs like spironolactone. Because ATS can arise from different underlying mechanisms, long-term care often requires multidisciplinary support. Future progress depends on improved hormonal testing, better understanding of genetic risk, and research into metabolic and endocrine pathways to aid earlier detection and personalised treatment.